A-share pharmaceutical stocks rebounded collectively, with recombinant proteins, CRO, biological products, innovative drugs and other concepts all seeing narrower declines; Jinbo Biopharmaceuticals rose by more than 3%, followed by Shanghai Laishi, Wantai Biopharmaceuticals, and Bidex Pharmaceuticals. Trump previously announced that drug tariffs could be as high as 200%.